Contact Lens & Vision
Woodbridge, New Jersey, 07095, United States
Location status: Recruiting
NCT Number: NCT07446582
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are:
* Does DeepMSI AI detect AMD biomarkers with sensitivity equivalent to experienced clinicians? * Does DeepMSI AI detect AMD biomarkers with specificity equivalent to experienced clinicians? Participants' eyes will be imaged by MSI-120 and their images will be analyzed for AMD biomarkers by both DeepMSI AI and retina specialists independently.
Researchers will compare retina image analysis from DeepMSI AI with ground truth (clinicians' interpretations) to see if AI achieves equivalency in sensitivity and specificity.
Interested in participating?
Request Info40 year and older
All sexes
Observational
Woodbridge, New Jersey, 07095, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
AMD subjects:
Healthy subjects:
Exclusion criteria
This is single-arm intervention where device use (acquiring retina images with MSI-120 device and analyzing retinal images with the DeepMSI AI) is the primary intervention to assess performance. To eliminate any potential risk to patients, AI outputs from this study will not be disclosed to treating clinicians or participants during the study period.
Time frame: through study completion, an average of 6 months
Assessment of equivalency in sensitivity and specificity of the DeepMSI AI system compared with experienced clinicians for detection of AMD biomarkers (including drusen, GA) at the eye level as identified on MSI images, using the consensus of two masked retina experts as the reference standard.
Contact information is provided by the study sponsor or research team.
Angela F. Esfandiarinezhad, PhD
CONTACT
Emily Zhang, MD. PhD
CONTACT
AI-Spectral
Industry
Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) at Point-of-Care to Identify and Quantify Biomarkers of Non-Exudative Age-Related Macular Degeneration
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07298291
Age-Related (Dry) Macular Degeneration, Eye Diseases
Erie, Pennsylvania, United States
View Trial DetailsNCT02540148
Age-Related (Dry) Macular Degeneration, Eye Diseases
Coquitlam, British Columbia, Canada
View Trial DetailsNCT07367282
Eye Diseases, Macular Degeneration
Seongnam, South Korea
View Trial DetailsNCT07440225
Age-Related Macular Degeneration, Choroid Diseases
Scottsdale, Arizona, United States
View Trial Details